Highlights Zealand Pharma A/S

Equities

ZEAL

DK0060257814

Market Closed - Nasdaq Copenhagen Other stock markets 10:59:33 2024-05-08 am EDT			5-day change	1st Jan Change
657.5 ^DKK	-0.38%		+6.13%	+76.18%

Apr. 04	U.S. Futures Up, European Stocks Flat as Powell Reiterates Room for Rate Cuts This Year	DJ
Mar. 20	Zealand Pharma A/S Approves Appointments to the Board	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Global markets live: Robinhood, Dollar General, KKR, Boeing, Oracle...	Mar. 14
Drugmakers deepen efforts to tap into booming market for obesity drugs	Feb. 27	RE
Zealand Pharma A/S Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 27	CI
Boehringer eyes obesity, fatty liver drug launch in 2027 or 2028	Feb. 26	RE
BOEHRINGER EXEC BROUILLON TELLS REUTERS IT IS NOT CLEAR YET WHET…	Feb. 26	RE
Zealand Pharma: positive results in NASH	Feb. 26	CF
Zealand shares surge on liver drug data from Boehringer pact	Feb. 26	RE
Zealand Pharma shares surge on liver disease drug trial data	Feb. 26	RE
Zealand Pharma A/S Announces Boehringer Ingelheim Survodutide Phase 2 Trial Shows 83% of Adults Treated a Statistically Significant Improvement of Metabolic Dysfunction-Associated Steatohepatitis	Feb. 26	CI
Zealand Pharma, a new competitor for Novo Nordisk?	Jan. 24
Weight loss drug windfall attracts pharma companies	Jan. 11	RE
Drugmakers plot way into obesity market with deals and development	Jan. 11	RE
Zealand says US FDA turns down drug for low blood sugar in infants	Dec. 23	RE
Zealand Pharma Files New Drug Application for Bowel Syndrome Therapy with US FDA	Dec. 22	MT
Roche enters obesity drugs race with $2.7 bln Carmot deal	Dec. 04	RE
Roche enters obesity drugs race with $2.7 bln Carmot deal	Dec. 04	RE
Zealand Pharma A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Boehringer Ingelheim and Zealand Pharma A/S Announces Initiation of Three Phase III Trials	23-10-05	CI
Zealand Pharma Says FDA Granted Priority Review Designation for Dasiglucagon in Congenital Hyperinsulinism	23-08-30	MT
US FDA Grants Priority Review Designation to Zealand Pharma's Hypoglycemia Drug for Infants	23-08-30	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Zealand Pharma A/S

Equities

ZEAL

DK0060257814

Highlights

Filters